Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL

NCT04342117 · clinicaltrials.gov ↗

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped Strategy Change

Conditions

Lymphoma, Small Lymphocytic
Lymphoma
Lymphoma, Non-Hodgkin
Chronic Lymphocytic Leukemia
Follicular Lymphoma

Interventions

DRUG: duvelisib
DRUG: PI3K inhibitor

Sponsor

SecuraBio